In a study of 91 patients with mature and immature T cell lymphomas, 31.8% were found to have activating mutations in the JAK/STAT3 pathway, with 13% having JAK3 mutations and 7.7% with JAK1 mutations. Here, STAT3 is linked to T-cell non-Hodgkin lymphoma.